Enhanced Efficacy of Direct-Acting Antivirals in Hepatitis C Patients by Coadministration of Black Cumin and Ascorbate as Antioxidant Adjuvants
The widespread adaptation of a new generation of direct-acting antiviral agents (DAAs) unveils a superlative effect in the eradication of the hepatitis C virus (HCV). However, this therapy has been reported to exhibit vigorous side effects that pose a risk in fleet recovery. This study was conducted...
Saved in:
Published in | Oxidative medicine and cellular longevity Vol. 2020; no. 2020; pp. 1 - 10 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Cairo, Egypt
Hindawi Publishing Corporation
2020
Hindawi John Wiley & Sons, Inc Hindawi Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The widespread adaptation of a new generation of direct-acting antiviral agents (DAAs) unveils a superlative effect in the eradication of the hepatitis C virus (HCV). However, this therapy has been reported to exhibit vigorous side effects that pose a risk in fleet recovery. This study was conducted to investigate the efficacy of DAAs: sofosbuvir (SOF) and ribavirin (RBV), along with black cumin (BLC) and ascorbate (ASC), as adjuvants on hematological parameters; oxidative stress markers such as total antioxidant status (TAS), superoxide dismutase (SOD), reduced (GSH) and oxidized (GSSG) glutathione (GSH), gamma-glutamyl transferase (GGT), and malondialdehyde (MDA); liver function markers such as aspartate transaminase (AST), alanine aminotransferase (ALT), bilirubin, and alkaline phosphatase (ALP); and viral load with determined genotypes. HCV-infected patients (n=30) were randomly divided into two equal groups: control group (n=15) and treatment group (n=15). The control group was subjected only to SOF and RBV (400 mg each/day). Synergistically, the treatment group was administered with adjuvant therapy of BLC (250 mg/day) and ASC (1000 mg/day) along with DAAs (400 mg each/day) for 8 weeks. All selected patients were subjected to sampling at pre- and posttreatment stages for the assessment of defined parameters. The data revealed that the BLC/ASC adjuvant therapy boosted the efficacy of DAAs by reducing the elevated levels of liver markers such as AST, ALT, ALP, and bilirubin in the treatment group compared with those in the control group (P>0.05). The adjuvant therapy synchronously showed an ameliorating effect on hematological parameters. The SOF/RBV with adjuvant therapy also demonstrated an increasing effect in the activity of SOD, TAS, and GSH and a decreasing effect for GSSG, GGT, and malondialdehyde (MDA; P>0.05) followed by curtailing a RT-PCR-quantified viral load. Our findings provide evidence that systemic administration of BLC/ASC efficiently alleviates hematological, serological, and antioxidant markers as well as the viral load in hepatitis C patients. This highlights a potentially novel role of BLC and ASC in palliating hepatitis C. |
---|---|
AbstractList | The widespread adaptation of a new generation of direct-acting antiviral agents (DAAs) unveils a superlative effect in the eradication of the hepatitis C virus (HCV). However, this therapy has been reported to exhibit vigorous side effects that pose a risk in fleet recovery. This study was conducted to investigate the efficacy of DAAs: sofosbuvir (SOF) and ribavirin (RBV), along with black cumin (BLC) and ascorbate (ASC), as adjuvants on hematological parameters; oxidative stress markers such as total antioxidant status (TAS), superoxide dismutase (SOD), reduced (GSH) and oxidized (GSSG) glutathione (GSH), gamma-glutamyl transferase (GGT), and malondialdehyde (MDA); liver function markers such as aspartate transaminase (AST), alanine aminotransferase (ALT), bilirubin, and alkaline phosphatase (ALP); and viral load with determined genotypes. HCV-infected patients (n=30) were randomly divided into two equal groups: control group (n=15) and treatment group (n=15). The control group was subjected only to SOF and RBV (400 mg each/day). Synergistically, the treatment group was administered with adjuvant therapy of BLC (250 mg/day) and ASC (1000 mg/day) along with DAAs (400 mg each/day) for 8 weeks. All selected patients were subjected to sampling at pre- and posttreatment stages for the assessment of defined parameters. The data revealed that the BLC/ASC adjuvant therapy boosted the efficacy of DAAs by reducing the elevated levels of liver markers such as AST, ALT, ALP, and bilirubin in the treatment group compared with those in the control group (P>0.05). The adjuvant therapy synchronously showed an ameliorating effect on hematological parameters. The SOF/RBV with adjuvant therapy also demonstrated an increasing effect in the activity of SOD, TAS, and GSH and a decreasing effect for GSSG, GGT, and malondialdehyde (MDA; P>0.05) followed by curtailing a RT-PCR-quantified viral load. Our findings provide evidence that systemic administration of BLC/ASC efficiently alleviates hematological, serological, and antioxidant markers as well as the viral load in hepatitis C patients. This highlights a potentially novel role of BLC and ASC in palliating hepatitis C. The widespread adaptation of a new generation of direct-acting antiviral agents (DAAs) unveils a superlative effect in the eradication of the hepatitis C virus (HCV). However, this therapy has been reported to exhibit vigorous side effects that pose a risk in fleet recovery. This study was conducted to investigate the efficacy of DAAs: sofosbuvir (SOF) and ribavirin (RBV), along with black cumin (BLC) and ascorbate (ASC), as adjuvants on hematological parameters; oxidative stress markers such as total antioxidant status (TAS), superoxide dismutase (SOD), reduced (GSH) and oxidized (GSSG) glutathione (GSH), gamma-glutamyl transferase (GGT), and malondialdehyde (MDA); liver function markers such as aspartate transaminase (AST), alanine aminotransferase (ALT), bilirubin, and alkaline phosphatase (ALP); and viral load with determined genotypes. HCV-infected patients ( = 30) were randomly divided into two equal groups: control group ( = 15) and treatment group ( = 15). The control group was subjected only to SOF and RBV (400 mg each/day). Synergistically, the treatment group was administered with adjuvant therapy of BLC (250 mg/day) and ASC (1000 mg/day) along with DAAs (400 mg each/day) for 8 weeks. All selected patients were subjected to sampling at pre- and posttreatment stages for the assessment of defined parameters. The data revealed that the BLC/ASC adjuvant therapy boosted the efficacy of DAAs by reducing the elevated levels of liver markers such as AST, ALT, ALP, and bilirubin in the treatment group compared with those in the control group ( > 0.05). The adjuvant therapy synchronously showed an ameliorating effect on hematological parameters. The SOF/RBV with adjuvant therapy also demonstrated an increasing effect in the activity of SOD, TAS, and GSH and a decreasing effect for GSSG, GGT, and malondialdehyde (MDA; > 0.05) followed by curtailing a RT-PCR-quantified viral load. Our findings provide evidence that systemic administration of BLC/ASC efficiently alleviates hematological, serological, and antioxidant markers as well as the viral load in hepatitis C patients. This highlights a potentially novel role of BLC and ASC in palliating hepatitis C. The widespread adaptation of a new generation of direct-acting antiviral agents (DAAs) unveils a superlative effect in the eradication of the hepatitis C virus (HCV). However, this therapy has been reported to exhibit vigorous side effects that pose a risk in fleet recovery. This study was conducted to investigate the efficacy of DAAs: sofosbuvir (SOF) and ribavirin (RBV), along with black cumin (BLC) and ascorbate (ASC), as adjuvants on hematological parameters; oxidative stress markers such as total antioxidant status (TAS), superoxide dismutase (SOD), reduced (GSH) and oxidized (GSSG) glutathione (GSH), gamma-glutamyl transferase (GGT), and malondialdehyde (MDA); liver function markers such as aspartate transaminase (AST), alanine aminotransferase (ALT), bilirubin, and alkaline phosphatase (ALP); and viral load with determined genotypes. HCV-infected patients ( n = 30 ) were randomly divided into two equal groups: control group ( n = 15 ) and treatment group ( n = 15 ). The control group was subjected only to SOF and RBV (400 mg each/day). Synergistically, the treatment group was administered with adjuvant therapy of BLC (250 mg/day) and ASC (1000 mg/day) along with DAAs (400 mg each/day) for 8 weeks. All selected patients were subjected to sampling at pre- and posttreatment stages for the assessment of defined parameters. The data revealed that the BLC/ASC adjuvant therapy boosted the efficacy of DAAs by reducing the elevated levels of liver markers such as AST, ALT, ALP, and bilirubin in the treatment group compared with those in the control group ( P > 0.05 ). The adjuvant therapy synchronously showed an ameliorating effect on hematological parameters. The SOF/RBV with adjuvant therapy also demonstrated an increasing effect in the activity of SOD, TAS, and GSH and a decreasing effect for GSSG, GGT, and malondialdehyde (MDA; P > 0.05 ) followed by curtailing a RT-PCR-quantified viral load. Our findings provide evidence that systemic administration of BLC/ASC efficiently alleviates hematological, serological, and antioxidant markers as well as the viral load in hepatitis C patients. This highlights a potentially novel role of BLC and ASC in palliating hepatitis C. The widespread adaptation of a new generation of direct-acting antiviral agents (DAAs) unveils a superlative effect in the eradication of the hepatitis C virus (HCV). However, this therapy has been reported to exhibit vigorous side effects that pose a risk in fleet recovery. This study was conducted to investigate the efficacy of DAAs: sofosbuvir (SOF) and ribavirin (RBV), along with black cumin (BLC) and ascorbate (ASC), as adjuvants on hematological parameters; oxidative stress markers such as total antioxidant status (TAS), superoxide dismutase (SOD), reduced (GSH) and oxidized (GSSG) glutathione (GSH), gamma-glutamyl transferase (GGT), and malondialdehyde (MDA); liver function markers such as aspartate transaminase (AST), alanine aminotransferase (ALT), bilirubin, and alkaline phosphatase (ALP); and viral load with determined genotypes. HCV-infected patients ( n = 30) were randomly divided into two equal groups: control group ( n = 15) and treatment group ( n = 15). The control group was subjected only to SOF and RBV (400 mg each/day). Synergistically, the treatment group was administered with adjuvant therapy of BLC (250 mg/day) and ASC (1000 mg/day) along with DAAs (400 mg each/day) for 8 weeks. All selected patients were subjected to sampling at pre- and posttreatment stages for the assessment of defined parameters. The data revealed that the BLC/ASC adjuvant therapy boosted the efficacy of DAAs by reducing the elevated levels of liver markers such as AST, ALT, ALP, and bilirubin in the treatment group compared with those in the control group ( P > 0.05). The adjuvant therapy synchronously showed an ameliorating effect on hematological parameters. The SOF/RBV with adjuvant therapy also demonstrated an increasing effect in the activity of SOD, TAS, and GSH and a decreasing effect for GSSG, GGT, and malondialdehyde (MDA; P > 0.05) followed by curtailing a RT-PCR-quantified viral load. Our findings provide evidence that systemic administration of BLC/ASC efficiently alleviates hematological, serological, and antioxidant markers as well as the viral load in hepatitis C patients. This highlights a potentially novel role of BLC and ASC in palliating hepatitis C. |
Audience | Academic |
Author | Akram, Qaiser Naseer, Rahat Ahmed, Sarfraz Younus, Muhammad Zahoor, Adeela Deng, Cun-Liang Nawaz, Sadia Ibrahim, Muhammad Ojha, Suvash Chandra |
AuthorAffiliation | 2 Department of Biochemistry, Bahauddin Zakariya University, Multan 60800, Pakistan 5 Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China 4 Institute of Biochemistry & Biotechnology, University of Veterinary and Animal Sciences, Lahore, 54000 Lahore, Pakistan 3 Department of Pathobiology, University of Veterinary and Animal Sciences, Lahore, 51600, Narowal Campus, Pakistan 1 Department of Basic Sciences, University of Veterinary and Animal Sciences, Lahore, 51600, Narowal Campus, Pakistan |
AuthorAffiliation_xml | – name: 1 Department of Basic Sciences, University of Veterinary and Animal Sciences, Lahore, 51600, Narowal Campus, Pakistan – name: 2 Department of Biochemistry, Bahauddin Zakariya University, Multan 60800, Pakistan – name: 3 Department of Pathobiology, University of Veterinary and Animal Sciences, Lahore, 51600, Narowal Campus, Pakistan – name: 4 Institute of Biochemistry & Biotechnology, University of Veterinary and Animal Sciences, Lahore, 54000 Lahore, Pakistan – name: 5 Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China |
Author_xml | – sequence: 1 fullname: Ojha, Suvash Chandra – sequence: 2 fullname: Deng, Cun-Liang – sequence: 3 fullname: Naseer, Rahat – sequence: 4 fullname: Nawaz, Sadia – sequence: 5 fullname: Younus, Muhammad – sequence: 6 fullname: Ibrahim, Muhammad – sequence: 7 fullname: Zahoor, Adeela – sequence: 8 fullname: Ahmed, Sarfraz – sequence: 9 fullname: Akram, Qaiser |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32566096$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkU2P0zAQhiO0iP2AG2dkiSMbdmzHSXxBCtnCIq0EBzhbjmO3Lq1dbKfQX8FfxqWlCzdOHtmPHs_Me1mcOe90UTzH8Bpjxm4IELhpoG04wY-KC8wrUgLn1dmpBjgvLmNcAtSUVPhJcU4Jq2vg9UXxc-YW0ik9opkxVkm1Q96gWxu0SmWnknVz1LlktzbIVUTWoTu9kckmG1GPPuVKuxTRsEO9l-PaOhtTyLfe7T1vV1J9Rf2U75F0I-qi8mGQSSMZf2v9DztKl1A3LqdtLuLT4rHJH-lnx_Oq-PJu9rm_K-8_vv_Qd_elqjhPJce1wU0eSOlGcUUpbisYKW9aNrIKD6zGcjCmVkaBYk0DlWk156xqCWgwlF4Vbw7ezTSs9ajyFHlAsQl2LcNOeGnFvy_OLsTcb0VDeN41yYKXR0Hw3yYdk1j6Kbjcs8g7Ji1khj5Qc7nSwjrjs0ytbVSiqyljLWBoM3V9oFTwMQZtTn1gEPuQxT5kcQw54y_-7v0E_0k1A68OwMK6UX63_6nTmdFGPtAEGGkJ_QVQPLq6 |
CitedBy_id | crossref_primary_10_1155_2022_2679154 crossref_primary_10_3390_antiox10030364 crossref_primary_10_2174_2215083810666230330161740 crossref_primary_10_1186_s40001_023_01295_0 crossref_primary_10_3390_cimb45040198 crossref_primary_10_1039_D1RA01324F crossref_primary_10_1016_j_biopha_2023_114664 crossref_primary_10_1177_20420986221107753 |
Cites_doi | 10.1016/j.pestbp.2014.10.013 10.1016/j.ecoenv.2011.04.003 10.1016/0891-5849(90)90131-2 10.1016/j.dld.2015.09.015 10.1002/hep.26141 10.3390/v6114227 10.3109/08923970903307552 10.1097/01.meg.0000231746.76136.4a 10.1097/MD.0000000000008861 10.1002/jcla.21510 10.2741/4160 10.11648/j.ajls.20150305.14 10.3748/wjg.15.5647 10.1301/00296640260130777 10.1111/liv.13212 10.4110/in.2013.13.2.70 10.1007/s12072-018-9861-2 10.25083/rbl/24.3/538.544 10.1016/S1875-5364(14)60077-7 10.1097/00002030-199813000-00013 10.1016/j.fct.2009.11.044 10.1016/S0021-9258(18)63504-5 10.1111/j.1469-0691.2010.03432.x 10.1016/j.cmi.2016.12.034 10.4097/kjae.2016.69.6.555 10.31989/ffhd.v5i3.174 10.2217/17460913.1.1.103 10.1016/j.jhep.2017.01.025 10.1016/j.neuro.2011.08.001 10.1016/j.aller.2011.07.002 10.1016/j.phymed.2010.01.002 10.5897/JEBR2012.0042 10.1016/j.jtumed.2014.08.004 10.1016/S0168-8278(99)80281-5 10.1080/07391102.2017.1305297 10.1017/S0007114500001422 10.1111/j.1472-8206.2008.00607.x 10.1016/j.jhep.2014.08.014 10.1093/ajcn/69.6.1086 10.1056/NEJMoa1208953 10.5897/jpp2015.0364 10.1016/S2221-1691(13)60075-1 10.17219/acem/40461 10.1152/ajpgi.00522.2005 10.1016/j.jhep.2007.10.011 10.1186/s12879-015-1311-3 10.1186/1479-5876-4-25 10.3748/wjg.v19.i16.2529 10.3390/v5020439 10.33594/000000140 10.1073/pnas.88.24.11003 10.1007/s10620-009-0833-1 10.1002/prca.201000049 |
ContentType | Journal Article |
Copyright | Copyright © 2020 Sarfraz Ahmed et al. COPYRIGHT 2020 John Wiley & Sons, Inc. Copyright © 2020 Sarfraz Ahmed et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0 Copyright © 2020 Sarfraz Ahmed et al. 2020 |
Copyright_xml | – notice: Copyright © 2020 Sarfraz Ahmed et al. – notice: COPYRIGHT 2020 John Wiley & Sons, Inc. – notice: Copyright © 2020 Sarfraz Ahmed et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0 – notice: Copyright © 2020 Sarfraz Ahmed et al. 2020 |
DBID | ADJCN RHU RHW RHX CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. M0S M1P M2O MBDVC PIMPY PQEST PQQKQ PQUKI PRINS Q9U 5PM |
DOI | 10.1155/2020/7087921 |
DatabaseName | الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals Hindawi Publishing Complete Hindawi Publishing Subscription Journals Hindawi Publishing Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Research Library Research Library (Corporate) ProQuest - Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Research Library ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | Publicly Available Content Database MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: RHX name: Hindawi Publishing url: http://www.hindawi.com/journals/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1942-0994 |
Editor | Saso, Luciano |
Editor_xml | – sequence: 1 givenname: Luciano surname: Saso fullname: Saso, Luciano – fullname: Luciano Saso |
EndPage | 10 |
ExternalDocumentID | A635580108 10_1155_2020_7087921 32566096 1205282 |
Genre | Randomized Controlled Trial Journal Article |
GeographicLocations | Pakistan |
GeographicLocations_xml | – name: Pakistan |
GrantInformation_xml | – fundername: Higher Education Commission, Pakistan – fundername: Bahauddin Zakariya University |
GroupedDBID | --- 24P 3V. 4.4 53G 5VS 7X7 88E 8FI 8FJ 8G5 AAFWJ AAJEY ABUWG ADBBV ADJCN ADRAZ AENEX AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU DIK DWQXO E3Z EBD EBS EJD EMOBN F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH H13 HMCUK HYE IAO IEA IHR INH INR IPNFZ ITC KQ8 M1P M2O M48 M~E O5R O5S OK1 PGMZT PIMPY PQQKQ PROAC PSQYO RHX RIG RNS RPM SV3 TR2 UKHRP RHU RHW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7XB 8FK K9. MBDVC PQEST PQUKI PRINS Q9U 5PM |
ID | FETCH-LOGICAL-c499t-916f17006ce7c9c331840d39785d541b561abff6cfc0c57704f8e9954820e0f33 |
IEDL.DBID | RPM |
ISSN | 1942-0900 |
IngestDate | Tue Sep 17 21:24:55 EDT 2024 Thu Oct 10 16:43:17 EDT 2024 Wed Oct 16 18:06:34 EDT 2024 Thu Sep 26 20:03:12 EDT 2024 Sat Sep 28 08:25:31 EDT 2024 Sun Jun 02 19:22:50 EDT 2024 Thu Sep 12 16:23:16 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2020 |
Language | English |
License | This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2020 Sarfraz Ahmed et al. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c499t-916f17006ce7c9c331840d39785d541b561abff6cfc0c57704f8e9954820e0f33 |
Notes | Academic Editor: Luciano Saso |
ORCID | 0000-0003-1289-2985 0000-0003-1925-1320 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290872/ |
PMID | 32566096 |
PQID | 2412807233 |
PQPubID | 2037493 |
PageCount | 10 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7290872 proquest_journals_2412807233 gale_infotracmisc_A635580108 crossref_primary_10_1155_2020_7087921 pubmed_primary_32566096 hindawi_primary_10_1155_2020_7087921 emarefa_primary_1205282 |
PublicationCentury | 2000 |
PublicationDate | 2020-00-00 |
PublicationDateYYYYMMDD | 2020-01-01 |
PublicationDate_xml | – year: 2020 text: 2020-00-00 |
PublicationDecade | 2020 |
PublicationPlace | Cairo, Egypt |
PublicationPlace_xml | – name: Cairo, Egypt – name: United States – name: New York |
PublicationTitle | Oxidative medicine and cellular longevity |
PublicationTitleAlternate | Oxid Med Cell Longev |
PublicationYear | 2020 |
Publisher | Hindawi Publishing Corporation Hindawi John Wiley & Sons, Inc Hindawi Limited |
Publisher_xml | – name: Hindawi Publishing Corporation – name: Hindawi – name: John Wiley & Sons, Inc – name: Hindawi Limited |
References | (42) 1969; 244 44 45 (26) 2010; 1 48 49 (15) 2017; 24 (57) 2000; 6 (14) 2014; 2 (2) 2014; 5 50 51 52 53 10 54 11 55 12 56 13 58 16 17 18 19 1 (31) 2009; 1 3 4 5 6 7 8 9 60 61 (64) 2017; 23 62 63 20 21 65 22 23 25 28 29 (46) 2008; 2 (24) 1996; 56 (47) 2012; 7 (59) 2017; 6 (39) 2010; 26 30 32 33 34 35 36 37 38 (27) 2003 40 41 43 |
References_xml | – ident: 58 doi: 10.1016/j.pestbp.2014.10.013 – ident: 50 doi: 10.1016/j.ecoenv.2011.04.003 – volume: 7 start-page: 146 issue: 4 year: 2012 ident: 47 publication-title: ARYA Atherosclerosis – ident: 43 doi: 10.1016/0891-5849(90)90131-2 – ident: 45 doi: 10.1016/j.dld.2015.09.015 – ident: 1 doi: 10.1002/hep.26141 – ident: 6 doi: 10.3390/v6114227 – ident: 32 doi: 10.3109/08923970903307552 – ident: 62 doi: 10.1097/01.meg.0000231746.76136.4a – volume: 2 start-page: 162 issue: 4 year: 2014 ident: 14 publication-title: Journal of Pharmaceutical Care – ident: 41 doi: 10.1097/MD.0000000000008861 – ident: 53 doi: 10.1002/jcla.21510 – volume: 1 start-page: 143 issue: 2 year: 2009 ident: 31 publication-title: International Journal of Physiology, Pathophysiology and Pharmacology – ident: 20 doi: 10.2741/4160 – volume: 5 issue: 217 year: 2014 ident: 2 publication-title: Journal of Blood Disorders and Transfusion – ident: 29 doi: 10.11648/j.ajls.20150305.14 – ident: 4 doi: 10.3748/wjg.15.5647 – ident: 60 doi: 10.1301/00296640260130777 – ident: 9 doi: 10.1111/liv.13212 – ident: 25 doi: 10.4110/in.2013.13.2.70 – ident: 35 doi: 10.1007/s12072-018-9861-2 – ident: 19 doi: 10.25083/rbl/24.3/538.544 – ident: 51 doi: 10.1016/S1875-5364(14)60077-7 – ident: 65 doi: 10.1097/00002030-199813000-00013 – ident: 49 doi: 10.1016/j.fct.2009.11.044 – volume: 244 start-page: 6049 issue: 22 year: 1969 ident: 42 publication-title: The Journal of Biological Chemistry doi: 10.1016/S0021-9258(18)63504-5 – volume: 24 start-page: 127 issue: 2 year: 2017 ident: 15 publication-title: Journal of Turgut Ozal medical Center – ident: 3 doi: 10.1111/j.1469-0691.2010.03432.x – volume: 23 start-page: 409.e5 issue: 6 year: 2017 ident: 64 publication-title: Clinical Microbiology and Infection doi: 10.1016/j.cmi.2016.12.034 – ident: 63 doi: 10.4097/kjae.2016.69.6.555 – ident: 40 doi: 10.31989/ffhd.v5i3.174 – ident: 61 doi: 10.2217/17460913.1.1.103 – ident: 37 doi: 10.1016/j.jhep.2017.01.025 – ident: 33 doi: 10.1016/j.neuro.2011.08.001 – ident: 30 doi: 10.1016/j.aller.2011.07.002 – ident: 34 doi: 10.1016/j.phymed.2010.01.002 – ident: 52 doi: 10.5897/JEBR2012.0042 – ident: 44 doi: 10.1016/j.jtumed.2014.08.004 – ident: 56 doi: 10.1016/S0168-8278(99)80281-5 – ident: 16 doi: 10.1080/07391102.2017.1305297 – ident: 22 doi: 10.1017/S0007114500001422 – volume: 6 start-page: 96 issue: 1 year: 2017 ident: 59 publication-title: Medicine – volume: 2 start-page: 198 issue: 4 year: 2008 ident: 46 publication-title: Global Veterinaria – ident: 38 doi: 10.1111/j.1472-8206.2008.00607.x – ident: 7 doi: 10.1016/j.jhep.2014.08.014 – ident: 21 doi: 10.1093/ajcn/69.6.1086 – volume: 1 start-page: 409 issue: 4 year: 2010 ident: 26 publication-title: Indian Journal of Natural Products and Resources – ident: 8 doi: 10.1056/NEJMoa1208953 – ident: 28 doi: 10.5897/jpp2015.0364 – ident: 13 doi: 10.1016/S2221-1691(13)60075-1 – volume: 6 start-page: 713 issue: 4 year: 2000 ident: 57 publication-title: Medical Science Monitor – ident: 17 doi: 10.17219/acem/40461 – ident: 11 doi: 10.1152/ajpgi.00522.2005 – ident: 12 doi: 10.1016/j.jhep.2007.10.011 – ident: 36 doi: 10.1186/s12879-015-1311-3 – volume: 26 start-page: 249 issue: 2 year: 2010 ident: 39 publication-title: Pakistan Journal of Medical Sciences – ident: 55 doi: 10.1186/1479-5876-4-25 – ident: 48 doi: 10.3748/wjg.v19.i16.2529 – ident: 5 doi: 10.3390/v5020439 – ident: 18 doi: 10.33594/000000140 – year: 2003 ident: 27 – ident: 23 doi: 10.1073/pnas.88.24.11003 – ident: 54 doi: 10.1007/s10620-009-0833-1 – ident: 10 doi: 10.1002/prca.201000049 – volume: 56 start-page: 1291 issue: 6 year: 1996 ident: 24 publication-title: Cancer Research |
SSID | ssj0063241 |
Score | 2.3109004 |
Snippet | The widespread adaptation of a new generation of direct-acting antiviral agents (DAAs) unveils a superlative effect in the eradication of the hepatitis C virus... |
SourceID | pubmedcentral proquest gale crossref pubmed hindawi emarefa |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1 |
SubjectTerms | Adjuvants, Pharmaceutic - pharmacology Adjuvants, Pharmaceutic - therapeutic use Antioxidants Antioxidants - pharmacology Antioxidants - therapeutic use Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Ascorbic Acid - administration & dosage Ascorbic Acid - adverse effects Ascorbic Acid - therapeutic use Aspartate Bilirubin Biomarkers - blood Complications and side effects Drugs Enzymes Ethylenediaminetetraacetic acid gamma-Glutamyltransferase - blood Glutathione - blood Hepacivirus - genetics Hepatitis C Hepatitis C virus Hepatitis C, Chronic - blood Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - physiopathology Hepatitis C, Chronic - virology HIV Human immunodeficiency virus Humans Infections Liver Liver cancer Liver Function Tests Malondialdehyde - metabolism Nigella sativa - chemistry Oxidative stress Oxidative Stress - drug effects Pathogenesis Patient compliance Ribavirin - therapeutic use Sofosbuvir - therapeutic use Superoxide Dismutase - metabolism Viruses |
SummonAdditionalLinks | – databaseName: Hindawi Publishing dbid: RHX link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1dS8MwFA06GPgifludch_mYzHrZ_ZYxmQIioiDvZU0TVgFO7Gbul_hX_betptuCvq2j_R27CS55yS3J4y1vbQTYNpKbIW5x_Y8I-0uSms7Ecpon7aaUnrA-eY2GAy965E_qk2Sip9b-JjtSJ7zy5CLsEsPjG8KQRb594PRYsIlw_FSV3U9h5Yd-KK-fe3alczT1E8SX8jlTNwckwZ-y35jmusFk98y0NUO266pI0QV1rtsQ-d7rFkdJjnfZx_9fFxu50OfbCGkmsPEQDWl2ZGi8maIcjosAmMXkOUw0FROPc0K6MFd5a9aQDKH3kSuWOpSnHKhD3oz_BxknkJUoGxNkKiCLMqwk_csRZQgSh9nr1Rcc8CGV_2H3sCuj1uwFcqeKU57gSG3vkDpUHWV65L4S5GvCD_1vU6CTEsmxgTKKK78MOSeEZrs5JBEaG5c95A18kmujxlge6ldJ-x0EuVx48hUax3gxUJIoYWx2MUCivi5ctWISzXi-zFBFteQWeyoxumrmcN9lIkWaxFuMQ1D_DMUDgoVR8SeMOVyYbF2jecf8VsLsON67BYx9iayCHJcF29f4b4M4iJDDFD1WSxc6RHLBuTWvfpNno1L125UMXhT5-R_v-yUbdHbarGnxRrTl5k-Q_ozTc7Lzv8JNev8Tg priority: 102 providerName: Hindawi Publishing – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3fa9swEBZbS2AvY93a1V069NA9msq2ZCtPww0pYbBSxgp9M7J-EBdmt3WyLX9F_-Xd2XLalLG9GVs-mZx0d9_p8h0hJ9xEKbitMtTge0LOnQonAK3DUmpnBR41GfyD89eLdH7Fv1yLa59wa31Z5WATO0NtGo058lPwNEjcEifJ59u7ELtG4emqb6HxkuzGEcdj2t2z2cXlt8EWIxd5B7kmPMaMBBtK34VA1M9OMyazSRxtOaWR_aHgQm2M9GiB8PhX9bcg9Hkt5RPndP6GvPZRJc37ZbBHXtj6LRn1fSbX78jDrF50J_10howRSq9p42hv7cJcY-UzzWvsIwGyW1rVdG6x0npZtXRKL3vq1ZaWazpt1BbbLsrpcoB0uoL7VNWG5i0g2hJiWKraTmzzuzKgQJqbm9VPrLvZJ1fns-_Teeg7MYQaENESLGLqkMgv1TbTE50kiAsNhDJSGMGjEoIwVTqXaqeZFlnGuJMWmeYgvrDMJckB2amb2h4SCuOVTeIsikrNmYuVsdam8LKUSlrpAvJpUEVx2xNuFB1QEaJAlRVeZQF57_X0OCxmAhBkQMaotwJ3KPwYGvaLLnIMrMAbMxmQE6_P_8gfD8ou_LZui8dFCNP3et8ISSB4TAEQBiTbWhGbAUjkvf2krhYdoTcAHJg0Pvr3lB_IK_zAPv8zJjvL-5U9hohoWX70y_4Pet0H5g priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3da9swED9KS2AvY2334TYbeugevSmWZCsPY5iQEgYte1igb0aWJeKxOW2drM1fsX95d_7IllK6N2PLZ6E76e4nnX8HcCaLUYxuKw8t-p5QSm_CMULrMNfWO0VHTQX94HxxGc_m8suVutqDvtpoN4D1o9CO6knNb398uL_ZfMYJ_6mZ8EoRfucfE66TMf1RfhBJIcnWL-T2PIE4yRvoNZYR7UzwPgX-wds7zmngfhq8MNvFerAgmHxXPhaMPsyp_MdJnb-A5110ydLWHA5hz1VHMGjrTW6O4fe0WjQn_mxKzBHGbtjSs3bVC1NLGdAsraieBMquWVmxmaOM61VZswn72lKw1izfsMnS7LDukpxmL5BN1nifmapgaY3INsdYlpm6Ebu8LwtUJEuL7-tflH_zEubn02-TWdhVZAgtIqMVroyxJ0K_2LrEjq0QhA8LDGm0KpQc5RiMmdz72HrLrUoSLr12xDiHcYbjXohXsF8tK_cGGLY3TkTJaJRbyX1kCudcjC9rbbTTPoD3vSqy65Z4I2sAi1IZqSzrVBbA605Pf5tFXCGSDGBIesvIdnAwLM4bm6UUYKFX5jqAs06f_5E_7JWd9daZoTURi1AkBH6-1ftWiMAgMkZgGECyYxHbBkTovfukKhcNsTcCHfxodPJ0x0_hGXWw3Qcawv7qdu3eYmS0yt81Rv8HORkIEg priority: 102 providerName: Scholars Portal |
Title | Enhanced Efficacy of Direct-Acting Antivirals in Hepatitis C Patients by Coadministration of Black Cumin and Ascorbate as Antioxidant Adjuvants |
URI | https://search.emarefa.net/detail/BIM-1205282 https://dx.doi.org/10.1155/2020/7087921 https://www.ncbi.nlm.nih.gov/pubmed/32566096 https://www.proquest.com/docview/2412807233 https://pubmed.ncbi.nlm.nih.gov/PMC7290872 |
Volume | 2020 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdtR2AvY9_zlgU9dI9uFEuylUfPuIRCSigrZE9GliXi0ThlTrblr9i_vDt_ZM0YDPZiG1s6G9-d7n7y-SdCzkUxCSFs5b6B2OML4bQ_BWjt58o4K_FTU4E_OM-vw9mtuFrK5QmR_b8wTdG-ycuL6m59UZWrprbyfm3GfZ3YeDFPICFkKgrGp-Q04ryH6O3wi_TjDcqaigAnIVhf7S4lAn02jqDrNMAVYjiE-5AhXf-DkDSwaw0H-jBED1YIjr-Xf0tB_6ykfBCaLp-SJ11OSeP22Z-RE1s9J4N2lcn9C_IzrVbNd36aIl-ENnu6cbQd6_zYYN0zjStcRQJk17Ss6MxinfW2rGlCFy3xak3zPU02-ohrF-U0M4A02cF5qquCxjXg2RwyWKrrRuzmR1mA-mhcfNl9w6qbl-T2Mv2UzPxuHQbfAB7awngYOqTxC42NzNRwjqiwgERGyUKKSQ4pmM6dC40zzMgoYsIpizxzkF1Y5jh_Rc6qTWXfEArtteVBNJnkRjAX6MJaG0JnpbSyynnkQ6-K7L6l28gamCJlhtrLOu155HWnp9_NAiYBP3pkiHrL0D_hZRjwFpPFmFZBLGbKI-edPv8hf9grO-ucus7AsJA7KOAcbt_q_SCktyWPREcWcWiANN7HV8C6Gzrvzprf_nfPd-QxPns7MTQkZ9uvO_seUqVtPgIHWUYj8iiOr9LPsP-YXi9u4OxcKNjezJajxnl-AUcJFZU |
link.rule.ids | 230,315,733,786,790,869,884,891,2236,4043,12083,21416,24346,27954,27955,27956,31752,33777,43343,43838,53825,53827,74100,74657 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELdgqGIviO8FCvhhPEZLYjtxn1BUdSqwTTxsUt8sxx9qJpEM0gL9K_iXuUvcjiIEb1HinKOefXe_8_V3hBxzm-bgtqrYgO-JOfc6ngC0jitpvBN41GTxD87nF_n8in9YiEVIuHWhrHJrE3tDbVuDOfIT8DRI3JIx9u7mS4xdo_B0NbTQuEvuccY4rvNisQNcyETeA64JzzAfkWwL34VAzJ-cFIksJlm655JG7rOGC70z0aMlguPv9d9C0D8rKX9zTacPyYMQU9JyWASPyB3XPCajocvk5gn5OWuW_Tk_nSFfhDYb2no62Lq4NFj3TMsGu0iA7I7WDZ07rLNe1R2d0k8D8WpHqw2dtnqPaxfl9BlAOl3DfaobS8sO8GwFESzVXS-2_VFbUB8t7fX6G1bdPCVXp7PL6TwOfRhiA3hoBfYw90jjlxtXmIlhDFGhhUBGCit4WkEIpivvc-NNYkRRJNxLhzxzEF24xDP2jBw0beOOCIXx2rGsSNPK8MRn2jrncnhZSi2d9BF5u1WFuhnoNlQPU4RQqDIVVBaR50FPt8OyRAB-jMgY9aZwf8KPYWC3GFViWAW-OJEROQ76_I_88VbZKmzqTt0uQZh-0PtOCIPQMQc4GJFib0XsBiCN9_6Tpl72dN4Ab2DS7MW_p3xD7s8vz8_U2fuLjy_JIX7skAkak4PV17V7BbHRqnrdb4BfiSUJbQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lj9MwEB7BoiIuiDeBAj4sx6jOw4l7QlFpVV6rPbBSb5bj2GqQSBbSAv0V_GVmErdLEYJblDjjqDOemc-efgNwmlZRhmGrDA3GnjBNnQ6nCK3DUhpnBR01VfQH5w9n2fIifbsSK1__1Pmyyr1P7B111RraI59gpCHiljhJJs6XRZy_Xry6_BJSByk6afXtNK7DDYySnNo45KsD-CJW8h58TdOY9ib4vgheCML_fJJzmU_j6Cg8jexnjRf64K5HawLK3-u_paN_VlX-FqYWd-C2zy9ZMRjEXbhmm3swGjpO7u7Dz3mz7s_82Zy4I7TZsdaxwe-FhaEaaFY01FECZXesbtjSUs31pu7YjJ0PJKwdK3ds1uoj3l2S0-8GstkW7zPdVKzoENuWmM0y3fVi2x91hapkRfVp-40qcB7AxWL-cbYMfU-G0CA22qBvzBxR-mXG5mZqkoQQYoVJjRSVSKMS0zFdOpcZZ7gRec5TJy1xzmGmYblLkodw0rSNfQwMx2ubxHkUlSblLtaVtTbDl6XU0koXwMu9KtTlQL2hesgihCKVKa-yAB55PV0Ni7lALBnAmPSmaK3ij2Fw5RhVUIqFcZnLAE69Pv8jf7xXtvILvFNX5ojTD3o_CEkwjcwQGgaQH1nEYQBReh8_aep1T-2NUAcnjZ_8e8oXcBNtX71_c_buKdyibx02hcZwsvm6tc8wTdqUz3v7_wUO9g2Z |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Enhanced+Efficacy+of+Direct-Acting+Antivirals+in+Hepatitis+C+Patients+by+Coadministration+of+Black+Cumin+and+Ascorbate+as+Antioxidant+Adjuvants&rft.jtitle=Oxidative+medicine+and+cellular+longevity&rft.au=Ahmed%2C+Sarfraz&rft.au=Zahoor%2C+Adeela&rft.au=Ibrahim%2C+Muhammad&rft.au=Younus%2C+Muhammad&rft.date=2020&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=1942-0900&rft.volume=2020&rft_id=info:doi/10.1155%2F2020%2F7087921&rft.externalDocID=A635580108 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1942-0900&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1942-0900&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1942-0900&client=summon |